Ly in the arterial phase but not in precontrast acquisitions was also drastically higher with gadoxetic acid than with gadobenate dimeglumine (unmatched, 27.4 [40 of 146] vs 4.4 [10 of 226]; matched, 27.7 [36 of 130] vs six.two [eight of 130]; P .001) (Table three, Fig 1). Both rates of substantial imaging artifacts (unmatched, 22.six [33 of 146] vs 3.1 [seven of 226], P .001; matched, 22.three [29 of 130] vs three.1 [four of 130]; P .001) and serious imaging artifacts (unmatched, 7.5 [11 of 146] vs 0.4 [one of 226]; P .01; 7.7 [10 of 130] vs 0 [none of 130] for severe artifacts; P .001) in the arterial phase have been considerably a lot more frequent with gadoxetic acid than with gadobenate dimeglumine. We compared the prevalence of substantial lower in Spo2 levels in individuals who underwent gadoxetic acid nhanced dynamic liver MR imaging. No significant distinction was observed between sufferers who had substantial artifacts inside the arterial phase (12.1 [four of 33]) and individuals who did not (7.1 [eight of 113]; P = .469) with gadoxetic acid, also as with gadobenate dimeglumine (14.three [one of seven] vs 8.7 [19 of 218]; P = .484). Gadoxetic Acid Administration and Image Degradation Among the individuals who received gadoxetic acid, substantial artifacts on arterial phase pictures were often linked with breath-holding failure: 28 patients failed breath holding amongst those who had substantial artifacts on gadoxetic acid nhanced arterial phase photos (n = 33) and six of seven for gadobenate dimeglumine (Fig 4). Extreme imaging artifacts had been observed only in patients who received gadoxetic acid and who failed breath holding throughout the arterial phase (Table 3, Fig four). Amongst the ten sufferers who self-reported dyspnea, only a single had extreme imaging artifacts. Multivariate analysis revealed that breath-hold failure was substantially associated with substantial artifacts (P .trans-Hexahydro-1H-furo[3,4-c]pyrrole Chemscene 001) and extreme artifacts (P .457613-78-4 Purity 001). Along with breath-hold failure, male sex (P = .023) and greater BMI (P = .021) have been associated with extreme artifacts.Radiology. Author manuscript; out there in PMC 2017 August 18.Motosugi et al.PageResults from Site BAuthor Manuscript Author Manuscript Author Manuscript Author ManuscriptAt web site B, adverse effects were self-reported in 4 of 130 individuals who received gadoxetic acid.PMID:24179643 All adverse effects have been self-limited. Two patients complained about dyspnea (1.5 [two of 130]) (Table two, Table 3). Two other individuals reported a warm sensation and abdominal discomfort. A substantial reduce in Spo2 levels was observed in 3 patients (two.3 ) for the duration of arterial phase imaging. Breath-holding failure occurred throughout the arterial phase in 21 individuals (16.2 ). Substantial and serious artifacts on arterial phase pictures had been observed in 20 (15.4 ) and 3 (2.3 ) of 130 sufferers, respectively. Compared with website A, a comparable association was observed among self-reported dyspnea, breath-hold failure, and substantial and severe artifacts on arterial phase images (Fig 4). Substantial artifacts have been regularly connected with breath-hold failure (70 [14 of 20]). All three individuals with severe artifacts failed breath holding in the course of arterial phase imaging. Two individuals with self-reported dyspnea had neither substantial nor serious artifacts.DiscussionIn this study, we confirmed that severe motion-related artifacts at arterial phase liver imaging are additional often observed with gadoxetic acid than with gadobenate dimeglumine. By assessing breath-hold fide.
